

CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone 121SLE]
Catalog # AH12860

Specification

CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody - With BSA and Azide - Product Information

Application	,2,3,4,
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	Mouse / IgM, kappa
Calculated MW	>400kDa KDa

CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody - With BSA and Azide - Additional Information

Storage

Store at 2 to 8°C. Antibody is stable for 24 months.

Precautions

CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.


CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody - With BSA and Azide - Protein Information


CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody - With BSA and Azide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

CA19-9 / Sialyl Lewisa (GI Tumor Marker) Antibody - With BSA and Azide - Images





Formalin-fixed, paraffin-embedded human Gastric Carcinoma stained with CA19-9 Monoclonal Antibody (121SLE).

CA19-9 / Sialyl Lewis^a (GI Tumor Marker) Antibody - With BSA and Azide - Background

CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewis^a structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewis^a and/or Lewis^b blood group antigens. In normal tissues, sialyl Lewis^a antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.

CA19-9 / Sialyl Lewis^a (GI Tumor Marker) Antibody - With BSA and Azide - References

Blood transfusion and Immunohaematology, Ph. Rouger, D Anstee and Ch. Salmon (Eds). Arnette, France 30 (5): 353-720 (1987). | Tumor Biol 19(5): 390420, (1998; TD-6 Workshop Report)